India's drug regulator, the Drugs Controller General of India (DCGI), has cleared the country's first dengue vaccine, QDENGA. The vaccine is designed to protect against all four types of the dengue virus. Dengue is a mosquito-borne viral disease that affects millions worldwide. India accounts for nearly one-third of the global dengue burden, according to the vaccine manufacturer. Rapid urbanisation, climate change, and widespread mosquito breeding have increased the risk of infection across the country. The vaccine is given as two injections of 0.5 ml each, administered under the skin three months apart. Symptoms of dengue include high fever, severe headache, pain behind the eyes, joint and muscle pain, and rash. Severe cases can lead to bleeding, organ failure, and death. The approval comes as a significant step in controlling the spread of the disease, which has no specific treatment. Health officials hope the vaccine will reduce the number of cases and hospitalisations. The vaccine is already approved in several other countries and has shown efficacy in clinical trials. The DCGI's clearance allows it to be marketed and distributed in India. Further details on pricing and availability are expected soon.